Daiichi Sankyo, ArQule in license agreement
Both the companies have jointly developed ARQ 092 by utlizing ArQule Kinase Inhibitor Platform (AKIP) technology, as per the agreement signed in November 2008. Daiichi Sankyo will retain
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.